top of page
EVI Blue Logo_edited.jpg

EndoVascular Instruments Inc.

Less Invasive,

longer lasting treatment for

Peripheral Arterial Disease

    EndoVascular Instruments Kit Advantages

    • Comparable patency to conventional bypass but at lower cost, less patient discomfort and shorter hospital stays

    • Superior patency to endovascular techniques

    • Can be used for first time procedures and revision of failed endovascular procedures.  Occluded stents can now be removed, significantly increasing the utility of this method.   

    EVI Products
    Ready For Manufacturing


    US Patent No.: 11,534,198 B2 was issued on December 27, 2022 for more effectively removing plaque and failed stents from arteries. 

    Five additional US patent applications are currently pending including:

    • A 3-Step Patent that builds on earlier 2-step patented method

    • Stent/Graft Design: An ePTFE graft with an ePTFE-covered distal stent. 



    Casper Summer 2_edited.jpg
    EVI Building A.jpg

    The Team

    Tom Headshot 2-23.jpg

    Tom Wiita, MBA

    President& CEO 

    Thomas A. Wiita, Chairman, President and CEO. Mr. Wiita is a serial entrepreneur with multiple successes in the medical device field, including Catheter Technology (the Groshong catheters acquired by CR Bard earning $6 to $1 returns for investors), Iomed, Inc. (ASE symbol IOX, later acquired by ReAble/Empi) and Catheter Innovations (PASV catheters acquired by Boston Scientific earning $3 to $1 returns on a short, two-year holding period).

    • LinkedIn

    Tom Kelly, PE

    R & D Engineering Consultant

    Mr. Kelly is an Engineering Consultant and assisted in the design, manufacturing and marketing for EVI. Kelly has served as a senior engineer and manager for companies involved in the design, manufacture and marketing of proprietary products for the health care industry. 


    Robert Delahunty, JD

    Legal Counsel

    Bob Delahunty is a shareholder of Parsons Behle & Latimer and is a member of the firm’s Corporate and Tax department. He advises and assists clients on business matters involving corporate, securities and general commercial law, with an emphasis on structuring, negotiating, and documenting complex transactions. He has advised companies that utilize emerging technology in a broad range of matters, including the purchase, sale and financing of businesses, mergers, proxy statements and SEC compliance work and complex licensing arrangements.

    Mr. Delahunty began practice as an associate with Sheppard, Mullin, Richter & Hampton in Los Angeles,California; became an associate and shareholder at the Salt Lake City law firm of Prince, Yeates & Geldzahler; and from 1982 until he joined Parsons in May of 1992, was a founding partner/shareholder of Hansen Jones & Leta.

    Nick 2.jpeg

    Nick Raible, MS

    Sales and Marketing Consultant

    Having worked for both WL Gore and Impra, Nick has expertise with ePTFE grafts and hemodynamics.  He has managed sales teams in the vascular market and provides strategic and tactical support to EndoVascular Instruments. 

    • LinkedIn
    John 2.JPEG

    John DeFeo

    Business Development Consultant

    John is a serial CEO & Venture Capitalist with extensive experience solving business problems and scaling start ups for growth.

    • LinkedIn


    Tom Wiita         
    President & CEO


    bottom of page